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Response to Letter to the Editor: ‘About oral absorption and human
pharmacokinetics of chondroitin sulfate’Dr Volpi’s comments will be considered one by one as
a Response under a restatement of each comment in italics:
1. “However, many previous studies on man [see Refs. 2 and 3],
animals4 and in vitro models5 using CS or similar natural bio-
macromolecules, i.e., dermatan sulfate, desulfated CS, fucosyl CS,
heparin, or mixtures [see Refs. 2 and 3] clearly demonstrated the
oral absorption of these polysaccharides. As a consequence, how is
it possible to explain the “absence” of CS oral absorption in man
observed in1?
Response
The previous studies on man (Refs. 2 and 3) are the only studies
considered relevant to the clinical study presented in this paper.
Studies on animals4 and in vitro5 or with non-CS polysaccharides,
while informative, are not directly relevant.
In both Refs. 2 and 3 the studies involved 20 healthy volunteers
given a single high dose (4000 mg) and plasma levels were deter-
mined over the ﬁrst 48 h.
This dosage is 10-fold higher than the single clinically-relevant
dose (400 mg) administered in GAIT. GAIT patients took oral doses
of 400 mg three times per day for a total of 1200 mg over approx-
imately 15 h.
It is for these dosage reasons that we did not refer to Dr Volpis
studies in our discussion, although we did acknowledge (our
Ref. 14) Dr Volpis development of an HPLC/MS method for analysis
of CS and HA disaccharides using 2-aminoacridine tagging, the
reagent used with FACE analysis in our paper.2. “Under these conditions and considering that Jackson et al.
determined a mean CS endogenous concentration of approx.
20 mg/ml with a possible individual variation of 5 mg/ml (25%)
and 40–45% variation in AUC values after CS administration (see
Tables IV and VI)1 (similar values to those obtained in studies2,3),
it is hard to obtain any signiﬁcant plasma CS variation. To
conﬁrm this, a trend towards higher CS concentrations was
observed by the authors but differences were found to be
non-signiﬁcant, also perhaps due to the small number of subjects,
9–10, studied1”.
Response
Dr Volpi has calculated (with inherent assumptions about the
pharmacokinetics of oral CS taken by GAIT patients) that when
compared to Dr Volpis own work with 4000 mg dosing, it is
not unexpected that there was no detectable change (above
endogenous levels) in plasma concentrations at the 400 mg 3
dosing regimen used in GAIT. This would appear to be conﬁrmed1063-4584/$ – see front matter  2010 Osteoarthritis Research Society International. Pu
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readers in the early paragraphs of the Discussion. We discussed
the total endogenous concentration of CS (10–20 mg/ml), and (if
the pharmacokinetics for CS and GlcN are similar) the expected
peak of absorbed CS (200 ng/ml), after oral dosing at 400 mg.
It should be noted however that we provide other data
(regarding the disaccharide composition) which also suggest
little or no absorption of oral CS when taken at clinically-relevant
doses.
3. “Along with detection limits, other factors may inﬂuence CS
recovery from plasma. For example, previous studies, contrary to
research in Ref. 1, accurately avoid the use of heparin (a poly-
saccharide with similar anionic properties to CS), interfering in
particular with the extraction procedures”.
Response
We are unaware of such previous studies and since no refer-
ences are provided by Dr Volpi we cannot answer this potential
criticism of our work.
4. “Furthermore, Jackson et al. measured a CS endogenous amount
ofw20 mg/ml1, virtually 2–4-times more than several other studies
performed by various analytical approaches [see Refs. 2 and 3].”
Response
We consider that the difference in mean concentration of
endogenous CS found in our studies (205 mg/ml) to those in Oste-
oarthritis and Cartilage 2002; 10: 768–777 (0.3–5.3 mg/ml), and
those in Osteoarthritis Cartilage 2003; 11: 433–441(1.53–3.37 mg/
ml) to be reasonable given the following considerations. Firstly,
the human populations under study are from different age groups,
different ethnic groups and in different countries with different
dietary patterns. In addition the Methods of CS isolation from the
plasma (acetone precipitation vs Superose 6 chromatography)
and the methods of quantitative analysis (FACE vs HPLC) were
different in the different studies. Given that these are different
multi-step biochemical methods, a difference between the concen-
trations determined in the two laboratories of 4-fold is not unex-
pected or cause for concern.
5. “Additionally, due to the anionic properties of these macro-
molecules, absorbed CS may interact with several blood compo-
nents, in particular with endothelium reported, for example, to
have the power to remove up to 80% heparin from circulation
after administration7. Finally, part of the absorbed CS reachingblished by Elsevier Ltd. All rights reserved.
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where polysaccharides are most recovered in experimental
animals8.”
Response
We are in agreement with Dr Volpi that there aremany potential
cellular activities in the gut, portal vein and post-hepatic circulation
which could markedly limit the circulating concentration of the
oral dose CS. We make reference to this point in the conclusions
section of the opening Summary to the paper.A. Plaas, D.O. Clegg, J. Sandy*
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